ABSTRACT
The title compound, 3-[4-chlorophenyl]-4-formyl-[1, 2, 3] oxadiazol-3-ium-5-olate 5 was synthesized under ultrasonication by formylation of 3-[4-chlorophenyl]-[1, 2, 3] oxadiazol-3-ium-5-olate 4 and characterized by spectral studies. The ultrasonic method of synthesis was found to be simple, ecofriendly, economical, reduces reaction time and gave good yield when compared with traditional methods of synthesis. Anticancer activity of the compounds were tested against 60 human tumor cell lines and compared with standard drug vincristine sulphate. Compound 5 was found to be active against CNS [SNB-75, %GI=46.71], renal [UO-31, %GI=31.52], non small cell lung [NCI-H522, %GI=25.65], leukemia [MOLT-4, %GI=23.02] human tumor cell lines whereas, compound 4 against breast [MDA-MB-231/ATCC, %GI=19.90, T-47D %GI=16.50, MCF-7 15.10] and ovarian [IGROV1 %GI=19.30, OVCAR-4 %GI=17.90] human tumor cell lines. Compound 5 showed higher cytotoxicity against NCI-H23 cells [non small lung cancer cell panel] as compared to standard drug vincristine sulphate. Further structural modification of these compounds may lead to potent anticancer activity